Citi analyst Yigal Nochomovitz said the resignation of Portola Pharmaceuticals’ CCO is a “clear positive” and is not much of a surprise given his lack of experience in commercial operations. The analyst believes Portola can now substantially re-shape top-level management with a new COO with the right operational experience ahead of both the Andexxa and Bevyxxa launches. Norchomovitz rates Portola Pharmaceuticals a Buy with a $50 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.